Arcadia Biosciences, Inc. (RKDA)
NASDAQ: RKDA · IEX Real-Time Price · USD
2.060
+0.100 (5.10%)
At close: Apr 19, 2024, 4:00 PM
1.950
-0.110 (-5.34%)
After-hours: Apr 19, 2024, 5:15 PM EDT
Company Description
Arcadia Biosciences, Inc. produces and markets plant-based food and beverage products in the United States.
The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients.
Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.
The company was incorporated in 2002 and is headquartered in Dallas, Texas.
Arcadia Biosciences, Inc.
Country | United States |
Founded | 2002 |
IPO Date | May 15, 2015 |
Industry | Packaged Foods |
Sector | Consumer Staples |
Employees | 21 |
CEO | Stanley E. Jacot Jr. |
Contact Details
Address: 202 Cousteau Place, Suite 105 Davis, X1 95618 X1 | |
Phone | 530-756-7077 |
Website | arcadiabio.com |
Stock Details
Ticker Symbol | RKDA |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001469443 |
CUSIP Number | 039014204 |
ISIN Number | US0390143032 |
Employer ID | 81-0571538 |
SIC Code | 0100 |
Key Executives
Name | Position |
---|---|
Stanley E. Jacot Jr. | President, Chief Executive Officer and Director |
Thomas J. Schaefer | Chief Financial Officer and Corporate Secretary |
Tracy Baker | Senior Vice President of Seamless Technical Operations |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 28, 2024 | 10-K | Annual Report |
Mar 28, 2024 | 8-K | Current Report |
Feb 14, 2024 | 8-K | Current Report |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Jan 3, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Nov 9, 2023 | 10-Q | Quarterly Report |
Nov 9, 2023 | 8-K | Current Report |
Aug 10, 2023 | 10-Q | Quarterly Report |
Aug 10, 2023 | 8-K | Current Report |
Jul 20, 2023 | 8-K | Current Report |